Tirzepatide
Structural profile, receptor binding kinetics, and cold-chain handling standards for Tirzepatide, a 39-amino acid synthetic dual GIP and GLP-1 receptor co-agonist.
Molecular Design & Dual-Incretin Architecture
Tirzepatide is a 39-amino acid synthetic linear peptide engineered from the native glucose-dependent insulinotropic polypeptide (GIP) sequence[cite: 13]. It incorporates two non-coded $\alpha$-aminoisobutyric acid ($\text{Aib}$) residues at positions 2 and 13 to resist dipeptidyl peptidase-4 ($\text{DPP-4}$) enzymatic degradation, alongside a $\text{C}_{20}$ fatty diacid moiety conjugated via a hydrophilic linker at $\text{Lys}^{20}$ to promote non-covalent albumin binding.
Receptor Binding & Second-Messenger Kinetics
In recombinant receptor-expressing cell lines, Tirzepatide demonstrates biased agonism favoring cyclic AMP ($\text{cAMP}$) accumulation over $\beta$-arrestin recruitment at the GLP-1 receptor, while maintaining full native potency at the GIP receptor:
$$\text{Response} = E_{\min} + \frac{E_{\max} - E_{\min}}{1 + 10^{(\log EC_{50} - \log [A]) \cdot n_H}}$$
- GIP Receptor Affinity: Comparable to native $\text{GIP}(1\text{–}42)$ ($K_i \approx 0.135\text{ nM}$).
- GLP-1 Receptor Affinity: Approximately 5-fold lower affinity than native $\text{GLP-1}(7\text{–}36)$ ($K_i \approx 4.23\text{ nM}$), resulting in reduced receptor desensitization and prolonged cAMP signaling.
- Metabolic Transcriptomics: Utilized to examine beta-cell insulin secretion kinetics, adipose tissue lipid partitioning, and hepatic gluconeogenic gene regulation.
Analytical Specifications & Storage
- Purity Standard: $\ge 99.8\%$ verified via RP-HPLC and ESI-MS[cite: 13].
- Storage Protocol: Maintain lyophilized vials sealed at $-20^\circ\text{C}$. Due to its high molecular weight ($4813.45\text{ g/mol}$) and amphiphilic fatty-diacid chain, swirl gently during reconstitution rather than vortexing to prevent peptide aggregation.
Related Research Requisition
Verify batch #NL-TIRZ10 COA metrics on the Tirzepatide Product Page[cite: 13].